ARTBIO
ARTBIO is a biotechnology company developing Alpha Radioligand Therapies for cancer, powered by Pb-212 isotope technology, including its lead asset AB001.
Secondary Market Price
How ARTBIO Measures Up
To help you manage your ARTBIO equity, Prospect has run the company through our machine learning model.
Prospect Rating
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series B
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of ARTBIO's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future ARTBIO Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for ARTBIO's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
ARTBIO is a biotechnology research company developing a new class of Alpha Radioligand Therapies (ARTs) that utilize Pb-212 isotope technology for cancer treatment. The company is currently conducting the Phase I ARTISAN clinical trial for its lead asset, AB001, in patients with metastatic castration-resistant prostate cancer (mCRPC). This trial involves ongoing dosing for two U.S.-based patient cohorts. A privately held company, ARTBIO is headquartered in Cambridge, Massachusetts, with additional offices in Oslo, Basel, and London. It has grown to a team of 51-200 employees and has completed three funding rounds, including a Series B round that raised $132.0 million in August 2025.
Looking ahead, ARTBIO plans to continue expanding its distributed manufacturing model across multiple continents to improve patient access to its therapies. The company is advancing its clinical and operational plans, a move underscored by recent announcements. In early 2026, Dr. Jonathan Freeman joined as Chief Business Officer to oversee corporate business development. ARTBIO also provided a dosing update for its ARTISAN trial, which is being conducted with partners BAMF Health, United Theranostics, and SpectronRx. Further clinical and preclinical updates are expected to be presented by CEO Emanuele Ostuni at the JPM2026 conference.
- Sofinnova Investments
- B Capital
- F-Prime
- Omega Funds
- Third Rock Ventures
- Qatar Investment Authority
- Alexandria Venture Investments
- Co-Founder, Roy Larsen
- Co-Founder, Øyvind Bruland
- Co-Founder, Emanuele Ostuni
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is ARTBIO worth joining?
Deciding to join a startup like ARTBIO depends on your personal career goals and risk tolerance, especially concerning the equity compensation package. Platforms like Prospect can help you understand the potential future value of your equity, which is a key part of your total compensation.
What should I do with my ARTBIO stock?
Managing your ARTBIO stock involves making strategic decisions about when to exercise options and how to plan for taxes to maximize your returns. Using a service like Prospect can provide customized strategies and tax optimization tools to help you make informed choices.
Can you sell ARTBIO stock?
As ARTBIO is a private company, selling your stock is typically possible only during specific events like a tender offer or on a secondary market, subject to company approval. Tools like Prospect can help you navigate these opportunities by providing access to secondary market data and helping you decide how much to sell in a tax-efficient manner.
How can I find the value of my ARTBIO stock?
The value of private stock like ARTBIO's is typically based on the company's latest 409A valuation, but this doesn't reflect its potential future worth. To get a better projection, you can use platforms like Prospect, which use predictive models and secondary market data to help you estimate your equity's value.
What is ARTBIO's equity worth?
The total worth of ARTBIO's equity is determined by its valuation from funding rounds and internal 409A assessments, which can change over time. Understanding your personal stake's worth requires analyzing your grant details and potential tax implications, which services like Prospect are designed to help with.
What is ARTBIO's stock ticker symbol?
ARTBIO does not have a stock ticker symbol because it is a private company and its shares are not traded on a public stock exchange. Ticker symbols are only assigned to companies when they become publicly listed through an Initial Public Offering (IPO).
Can I buy or sell ARTBIO stock?
Buying or selling shares in a private company like ARTBIO is restricted and typically only occurs during specific liquidity events, such as secondary sales or tender offers. Platforms like Prospect offer tools that can help you understand and prepare for these opportunities to sell your shares tax-optimally.
What is the criteria to buy or invest in ARTBIO stock?
Investing in a private company like ARTBIO is generally limited to accredited investors and venture capital firms during official funding rounds. For employees who receive equity as compensation, the focus is on managing that stock, and tools from Prospect can help create a strategy for your existing shares.
